Capricor Therapeutics (NASDAQ:CAPR) Shares Down 6% – What’s Next?

Capricor Therapeutics Inc (NASDAQ:CAPR) shares dropped 6% on Tuesday . The stock traded as low as $11.90 and last traded at $12.11. Approximately 317,967 shares were traded during mid-day trading, a decline of 77% from the average daily volume of 1,357,926 shares. The stock had previously closed at $12.88.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and set a $77.00 target price on shares of Capricor Therapeutics in a research report on Monday. One equities research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $34.50.

Capricor Therapeutics Stock Down 6.9 %

The stock has a market cap of $545.19 million, a P/E ratio of -11.31 and a beta of 4.10. The stock has a fifty day simple moving average of $14.14 and a 200-day simple moving average of $14.46.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of CAPR. Summit Investment Advisors Inc. boosted its position in shares of Capricor Therapeutics by 54.1% during the fourth quarter. Summit Investment Advisors Inc. now owns 3,832 shares of the biotechnology company’s stock worth $53,000 after purchasing an additional 1,345 shares in the last quarter. The Manufacturers Life Insurance Company increased its position in shares of Capricor Therapeutics by 22.4% in the 4th quarter. The Manufacturers Life Insurance Company now owns 12,919 shares of the biotechnology company’s stock valued at $178,000 after buying an additional 2,361 shares in the last quarter. Invesco Ltd. raised its stake in Capricor Therapeutics by 20.5% during the 4th quarter. Invesco Ltd. now owns 14,678 shares of the biotechnology company’s stock worth $203,000 after buying an additional 2,500 shares during the period. Russell Investments Group Ltd. raised its stake in Capricor Therapeutics by 172.8% during the 4th quarter. Russell Investments Group Ltd. now owns 4,652 shares of the biotechnology company’s stock worth $64,000 after buying an additional 2,947 shares during the period. Finally, Corebridge Financial Inc. lifted its holdings in Capricor Therapeutics by 32.2% during the fourth quarter. Corebridge Financial Inc. now owns 18,212 shares of the biotechnology company’s stock worth $251,000 after acquiring an additional 4,434 shares in the last quarter. Institutional investors own 21.68% of the company’s stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.